Table 1.
Baseline demographics
| Category | Value |
|---|---|
| Age, median, years | 50.5 |
| Age range, years | 29–65 |
| Functional class II | 4 (34) |
| Functional class III | 8 (66) |
| Race | |
| White | 10 (83) |
| African American | 1 (8) |
| Hispanic | 1 (8) |
| Etiology | |
| Idiopathic PAH | 5 (40) |
| Hereditary PAH | 1 (8) |
| Drug/toxin PAH | 1 (8) |
| Connective-tissue disease | 3 (13) |
| Congenital heart disease | 2 (17) |
| PAH medications | |
| Monotherapy | 7 (58) |
| PDE 5I | 3 (25) |
| ERA | 1 (8) |
| IV/SC prostacyclin | 3 (25) |
| Combination therapy | 5 (42) |
| ERA–PDE 5I | 1 (8) |
| PDE 5I–IV/SC prostacyclin | 4 (33) |
Note
Data are no. (%) of patients unless otherwise indicated. ERA: endothelin receptor antagonist; IV: intravenous; PAH: pulmonary arterial hypertension; PDE 5I: phosphodiesterase 5 inhibitor; SC: subcutaneous.